MX391970B - Interferon porcino pegilado y metodos de utilizacion del mismo. - Google Patents
Interferon porcino pegilado y metodos de utilizacion del mismo.Info
- Publication number
- MX391970B MX391970B MX2018016295A MX2018016295A MX391970B MX 391970 B MX391970 B MX 391970B MX 2018016295 A MX2018016295 A MX 2018016295A MX 2018016295 A MX2018016295 A MX 2018016295A MX 391970 B MX391970 B MX 391970B
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- same
- pinf
- porcine interferon
- variants
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 2
- 102000014150 Interferons Human genes 0.000 title 1
- 108010050904 Interferons Proteins 0.000 title 1
- 229940079322 interferon Drugs 0.000 title 1
- 150000001413 amino acids Chemical class 0.000 abstract 2
- 102000006992 Interferon-alpha Human genes 0.000 abstract 1
- 108010047761 Interferon-alpha Proteins 0.000 abstract 1
- 108010076504 Protein Sorting Signals Proteins 0.000 abstract 1
- 241000282887 Suidae Species 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 238000003780 insertion Methods 0.000 abstract 1
- 230000037431 insertion Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000009385 viral infection Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/212—IFN-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
- C07K14/56—IFN-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Communicable Diseases (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Inorganic Chemistry (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662352163P | 2016-06-20 | 2016-06-20 | |
| PCT/US2017/037964 WO2017222940A1 (en) | 2016-06-20 | 2017-06-16 | Pegylated porcine interferon and methods of use thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2018016295A MX2018016295A (es) | 2019-09-16 |
| MX391970B true MX391970B (es) | 2025-03-21 |
Family
ID=59258379
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018016295A MX391970B (es) | 2016-06-20 | 2017-06-16 | Interferon porcino pegilado y metodos de utilizacion del mismo. |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US10960080B2 (enExample) |
| EP (1) | EP3471755B1 (enExample) |
| JP (2) | JP7093311B2 (enExample) |
| KR (2) | KR102518451B1 (enExample) |
| CN (2) | CN109641034B (enExample) |
| AU (2) | AU2017280958A1 (enExample) |
| BR (1) | BR112018076437A2 (enExample) |
| CA (1) | CA3028683A1 (enExample) |
| CL (1) | CL2018003697A1 (enExample) |
| DK (1) | DK3471755T3 (enExample) |
| EA (1) | EA036509B1 (enExample) |
| ES (1) | ES2793773T3 (enExample) |
| MX (1) | MX391970B (enExample) |
| NZ (1) | NZ749962A (enExample) |
| PL (1) | PL3471755T3 (enExample) |
| PT (1) | PT3471755T (enExample) |
| WO (1) | WO2017222940A1 (enExample) |
| ZA (1) | ZA201808352B (enExample) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2928164T3 (es) | 2015-10-19 | 2022-11-15 | Incyte Corp | Compuestos heterocíclicos como inmunomoduladores |
| HUE060680T2 (hu) | 2015-11-19 | 2023-04-28 | Incyte Corp | Heterociklusos vegyületek mint immunmodulátorok |
| DK3394033T3 (da) | 2015-12-22 | 2021-01-04 | Incyte Corp | Heterocykliske forbindelser som immunmodulatorer |
| MA44860A (fr) | 2016-05-06 | 2019-03-13 | Incyte Holdings Corp | Composés hétérocycliques utilisés comme immunomodulateurs |
| WO2017205464A1 (en) | 2016-05-26 | 2017-11-30 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| SG11201811414TA (en) | 2016-06-20 | 2019-01-30 | Incyte Corp | Heterocyclic compounds as immunomodulators |
| ES2930092T3 (es) | 2016-07-14 | 2022-12-07 | Incyte Corp | Compuestos heterocíclicos como inmunomoduladores |
| EP3504198B1 (en) | 2016-08-29 | 2023-01-25 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| MD3558990T2 (ro) | 2016-12-22 | 2023-02-28 | Incyte Corp | Derivați tetrahidro imidazo[4,5-c]piridină ca inductori de internalizare a PD-L1 |
| US20180179179A1 (en) | 2016-12-22 | 2018-06-28 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| EP3558989B1 (en) | 2016-12-22 | 2021-04-14 | Incyte Corporation | Triazolo[1,5-a]pyridine derivatives as immunomodulators |
| MA47123A (fr) | 2016-12-22 | 2021-03-17 | Incyte Corp | Dérivés de benzooxazole en tant qu'mmunomodulateurs |
| CA3047991A1 (en) | 2016-12-22 | 2018-06-28 | Incyte Corporation | Bicyclic heteroaromatic compounds as immunomodulators |
| US10669271B2 (en) | 2018-03-30 | 2020-06-02 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| LT3790877T (lt) | 2018-05-11 | 2023-05-10 | Incyte Corporation | Tetrahidro-imidazo[4,5-c]piridino dariniai kaip pd-l1 imunomoduliatoriai |
| TW202115059A (zh) | 2019-08-09 | 2021-04-16 | 美商英塞特公司 | Ｐｄ—１／ｐｄ—ｌ１抑制劑之鹽 |
| CN110343164A (zh) * | 2019-08-22 | 2019-10-18 | 安阳工学院 | 一种高活性7位点突变的猪干扰素α突变体及其制备方法和应用 |
| EP4037773A1 (en) | 2019-09-30 | 2022-08-10 | Incyte Corporation | Pyrido[3,2-d]pyrimidine compounds as immunomodulators |
| PE20230407A1 (es) | 2019-11-11 | 2023-03-07 | Incyte Corp | Sales y formas cristalinas de un inhibidor de pd-1/pd-l1 |
| US11780836B2 (en) | 2020-11-06 | 2023-10-10 | Incyte Corporation | Process of preparing a PD-1/PD-L1 inhibitor |
| WO2022099075A1 (en) | 2020-11-06 | 2022-05-12 | Incyte Corporation | Crystalline form of a pd-1/pd-l1 inhibitor |
| WO2022099071A1 (en) | 2020-11-06 | 2022-05-12 | Incyte Corporation | Process for making a pd-1/pd-l1 inhibitor and salts and crystalline forms thereof |
| CN113845599B (zh) * | 2021-11-01 | 2023-09-19 | 长春萤火虫生物科技有限公司 | 一种重组猪干扰素融合蛋白及其应用 |
| WO2024241086A1 (en) | 2023-05-24 | 2024-11-28 | Ambrx, Inc. | Pegylated bovine interferon lambda and methods of use thereof |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6858409B1 (en) * | 1988-05-27 | 2005-02-22 | Amgen Inc. | Nucleic acids encoding interleukin-1 inhibitors and processes for preparing interleukin-1 inhibitors |
| AU691225B2 (en) * | 1993-11-10 | 1998-05-14 | Schering Corporation | Improved interferon polymer conjugates |
| US5908621A (en) * | 1995-11-02 | 1999-06-01 | Schering Corporation | Polyethylene glycol modified interferon therapy |
| JP2006213597A (ja) | 2000-07-19 | 2006-08-17 | Pepgen Corp | インターフェロン−タウを用いるｃ型肝炎ウイルスの処置のための組成物およびモニタリングの方法 |
| US20050226845A1 (en) * | 2004-03-10 | 2005-10-13 | Chih-Ping Liu | Method of treatment using interferon-tau |
| WO2005074546A2 (en) | 2004-02-02 | 2005-08-18 | Ambrx, Inc. | Modified human growth hormone polypeptides and their uses |
| KR20080026135A (ko) | 2005-06-03 | 2008-03-24 | 암브룩스, 인코포레이티드 | 개선된 인간 인터페론 분자 및 이의 용도 |
| US7695710B2 (en) | 2005-06-20 | 2010-04-13 | Pepgen Corporation | Antitumor and antiviral combination therapies using low-toxicity, long-circulating human interferon-alpha analogs |
| US8106160B2 (en) | 2007-10-01 | 2012-01-31 | Pharmaessentia Corp. | N-terminal modified interferon-alpha |
| AU2009274076C1 (en) | 2008-07-23 | 2014-04-17 | Ambrx, Inc. | Modified bovine G-CSF polypeptides and their uses |
| CN104262480B (zh) | 2014-09-28 | 2018-03-27 | 重庆理工大学 | 重组猪长效‑α干扰素的构建和修饰方法及其冻干注射剂的制备方法 |
-
2017
- 2017-06-16 ES ES17734584T patent/ES2793773T3/es active Active
- 2017-06-16 KR KR1020227019809A patent/KR102518451B1/ko active Active
- 2017-06-16 AU AU2017280958A patent/AU2017280958A1/en not_active Abandoned
- 2017-06-16 EA EA201892671A patent/EA036509B1/ru unknown
- 2017-06-16 BR BR112018076437A patent/BR112018076437A2/pt unknown
- 2017-06-16 PT PT177345840T patent/PT3471755T/pt unknown
- 2017-06-16 MX MX2018016295A patent/MX391970B/es unknown
- 2017-06-16 KR KR1020187036853A patent/KR102409470B1/ko active Active
- 2017-06-16 WO PCT/US2017/037964 patent/WO2017222940A1/en not_active Ceased
- 2017-06-16 DK DK17734584.0T patent/DK3471755T3/da active
- 2017-06-16 CN CN201780051072.0A patent/CN109641034B/zh active Active
- 2017-06-16 JP JP2018566519A patent/JP7093311B2/ja active Active
- 2017-06-16 EP EP17734584.0A patent/EP3471755B1/en active Active
- 2017-06-16 CN CN202310995289.4A patent/CN117024562A/zh active Pending
- 2017-06-16 US US16/311,540 patent/US10960080B2/en active Active
- 2017-06-16 CA CA3028683A patent/CA3028683A1/en active Pending
- 2017-06-16 PL PL17734584T patent/PL3471755T3/pl unknown
- 2017-06-16 NZ NZ749962A patent/NZ749962A/en unknown
-
2018
- 2018-12-11 ZA ZA2018/08352A patent/ZA201808352B/en unknown
- 2018-12-19 CL CL2018003697A patent/CL2018003697A1/es unknown
-
2021
- 2021-02-26 US US17/186,642 patent/US20210177980A1/en active Pending
- 2021-09-06 AU AU2021229132A patent/AU2021229132B2/en active Active
-
2022
- 2022-06-17 JP JP2022098147A patent/JP7441892B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US20210177980A1 (en) | 2021-06-17 |
| CN109641034B (zh) | 2023-08-15 |
| KR20220086700A (ko) | 2022-06-23 |
| KR102518451B1 (ko) | 2023-04-04 |
| KR20190039889A (ko) | 2019-04-16 |
| CN109641034A (zh) | 2019-04-16 |
| US10960080B2 (en) | 2021-03-30 |
| CL2018003697A1 (es) | 2019-05-10 |
| AU2021229132B2 (en) | 2023-04-06 |
| AU2021229132A1 (en) | 2021-09-30 |
| NZ749962A (en) | 2020-06-26 |
| DK3471755T3 (da) | 2020-05-18 |
| JP7441892B2 (ja) | 2024-03-01 |
| EP3471755A1 (en) | 2019-04-24 |
| EP3471755B1 (en) | 2020-04-22 |
| JP2019519553A (ja) | 2019-07-11 |
| JP2022137063A (ja) | 2022-09-21 |
| JP7093311B2 (ja) | 2022-06-29 |
| EA201892671A1 (ru) | 2019-05-31 |
| CA3028683A1 (en) | 2017-12-28 |
| KR102409470B1 (ko) | 2022-06-16 |
| ZA201808352B (en) | 2020-08-26 |
| MX2018016295A (es) | 2019-09-16 |
| WO2017222940A1 (en) | 2017-12-28 |
| US20190192673A1 (en) | 2019-06-27 |
| AU2017280958A1 (en) | 2018-12-20 |
| PT3471755T (pt) | 2020-05-22 |
| PL3471755T3 (pl) | 2020-10-19 |
| BR112018076437A2 (pt) | 2019-10-01 |
| CN117024562A (zh) | 2023-11-10 |
| EA036509B1 (ru) | 2020-11-18 |
| ES2793773T3 (es) | 2020-11-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX391970B (es) | Interferon porcino pegilado y metodos de utilizacion del mismo. | |
| PH12019501414A1 (en) | Amino acid compositions and methods for the treatment of liver diseases | |
| EA201591702A1 (ru) | Комбинация двух противовирусных препаратов для лечения гепатита c | |
| PE20170471A1 (es) | Polipeptidos receptores formulados y metodos relacionados | |
| MX2019006515A (es) | Composiciones que comprenden peptido wkdeagkplvk. | |
| MX2019006943A (es) | Polipéptidos para manejo de infecciones virales. | |
| EA201591752A1 (ru) | Дипептидные и трипептидные эпоксикетонные ингибиторы протеазы | |
| MX2021008207A (es) | Proteínas de fusión multifuncionales y usos de las mismas. | |
| EA201591701A1 (ru) | Комбинация противовирусных препаратов прямого действия и рибавирина для лечения пациентов с hcv | |
| EA201990885A1 (ru) | Композиции, содержащие короткие пептиды, полученные из pedf, и их применение | |
| IN2013MU03583A (enExample) | ||
| MX2018011162A (es) | Metodos de purificacion de colageno 7. | |
| NZ756128A (en) | Novel peptides and analogs for use in the treatment of oral mucositis | |
| SG10201809099PA (en) | Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage | |
| EA201590601A1 (ru) | Применение pedf-производных полипептидов для лечения остеоартрита | |
| WO2018105941A3 (ko) | 탈모방지 또는 발모촉진용 주사용 조성물 | |
| BR112015022196A2 (pt) | composições de liberação prolongada, que compreendem hidrocodona e acetaminofeno para rápido início e analgesia prolongada, que podem ser administradas independentemente de alimentos | |
| PH12017502323B1 (en) | Novel xylanase | |
| EP4219534A3 (en) | Methods for treatment of and prophylaxis against inflammatory disorders | |
| MX2018013177A (es) | Proteina de fusion que contiene variante ccl3 y uso de la misma referencia cruzada para aplicaciones relacionadas. | |
| IN2015DN01371A (enExample) | ||
| EA202092366A1 (ru) | Применение происходящих из pedf коротких пептидов при лечении остеоартрита | |
| WO2014172309A3 (en) | Therapeutic compositions for neutralizing type i interferons, and methods of use | |
| ES2526109R2 (es) | Péptido y composición farmacéutica para el tratamiento del cáncer | |
| EA202092368A1 (ru) | Применение происходящих из pedf коротких пептидов при заживлении сухожилий |